To explore the potential involvement of aberrant Notch1 signaling in breast cancer pathogenesis, we have used a transgenic mouse model. In these animals, mouse mammary tumor virus LTR-driven expression of the constitutively active intracellular domain of the Notch1 receptor (N1 IC ) causes development of lactation-dependent mammary tumors that regress upon gland involution but progress to nonregressing, invasive adenocarcinomas in subsequent pregnancies. Up-regulation of Myc in these tumors prompted a genetic investigation of a potential Notch1͞Myc functional relationship in breast carcinogenesis. Conditional ablation of Myc in the mammary epithelium prevented the induction of regressing N1 IC neoplasms and also reduced the incidence of nonregressing carcinomas, which developed with significantly increased latency. Molecular analyses revealed that both the mouse and human Myc genes are direct transcriptional targets of N1 IC acting through its downstream Cbf1 transcriptional effector. Consistent with this mechanistic link, Notch1 and Myc expression is positively correlated by immunostaining in 38% of examined human breast carcinomas.
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breast cancer ͉ mouse model T he Notch signaling pathway controls cell fates through interactions between neighboring cells by positively or negatively affecting, and in a context-dependent fashion, processes of proliferation, differentiation, and apoptosis (1, 2) . In mammals, each of four Notch receptors (Notch1-4) is synthesized as a precursor that is proteolytically processed to a cell membrane heterodimer. Two additional cleavages in response to ligand interaction release the Notch intracellular domain (N IC ), which translocates to the nucleus and modulates the expression of target genes predominantly by binding and converting the ubiquitous Cbf1 repressor (also known as Csl, Rbp-Jk, Rbpsuh, etc.) to a transcriptional activator (3) .
Deregulation of Notch signaling has been implicated in the development of lymphoid neoplasms, neuroblastomas, and various epithelial cancers, including mammary tumors (4, 5) . However, in contrast to some human malignancies, such as leukemia͞ lymphoma, in which an involvement of aberrant Notch function has been established (6) , evidence suggesting a role of this pathway in breast cancer is only now emerging. Thus, appreciable expression of Notch1 has been detected in the majority of examined ductal carcinoma in situ cases (see ref. 5 ) and in ductal carcinomas (7) but not in normal breast tissue. Interestingly, high Notch1 expression in breast cancers correlated significantly with poor survival of patients (8) . The potential involvement of Notch1 in breast cancer pathogenesis was strengthened by the observation that the Notch1 antagonist Numb was greatly reduced or absent in more than half of examined carcinomas, and this correlated with increased Notch1 signaling (9) . Moreover, the proliferative potential of cells derived from such tumors was dramatically suppressed by pharmacological inhibition of Notch1 (9) . In addition to these correlations, compelling evidence for tumorigenic action of Notch in the mammary epithelium has been derived from animal studies (10) (11) (12) .
Previously, we generated a mouse model in which all mammary glands of transgenic females expressing a constitutively active Notch1 IC (N1 IC ) transgene driven by the mouse mammary tumor virus (MMTV) LTR develop lactation-dependent papillary tumors that are noninvasive and regress upon gland involution (12) . After additional pregnancies, however, multifocal invasive (nonregressing) tumors also appear, apparently evolving from remnants of N1 IC -induced in situ neoplasms through the occurrence of secondary tumorigenic events.
By using a combination of genetic and molecular analyses, we started investigating the mechanisms involved in the pathogenesis of N1 IC -induced tumors and report here that one of the events mediating the development of premalignant neoplasms and later collaborating in the evolution of nonregressing invasive carcinomas is the direct transcriptional activation of Myc by Notch1.
Results

Up-Regulation of Myc Expression in N1 IC -Induced Mammary Tumors.
By using microarray analysis, we compared a set of expression profiles of murine mammary tumors. In addition to N1 IC -induced regressing and nonregressing neoplasms, we examined adenocarcinomas caused either by expression of MMTV LTR-driven oncogenes, including polyomavirus middle T antigen (13) , Myc (14) , Hras1 (15) , and activated Erbb2 (16), or by ablation of the tumorsuppressors p53 and Brca2 (17) . Our results (data not shown) revealed that the N1 IC tumors exhibited a high degree of profile similarity only with the carcinomas induced by Myc overexpression. Moreover, differentially expressed transcripts corresponding to transcriptional target genes known to be activated or repressed by Myc were commonly detected in the profiles of Myc-and N1 ICinduced tumors (see Fig. 6 and Tables 3 and 4 , which are published as supporting information on the PNAS web site). Notably, in addition to MMTV-Myc-induced cancers, Myc expression was found to be increased in regressing and nonregressing N1 IC neoplasms but not in the other examined tumor types. These observations were confirmed by Northern blot analysis (Fig. 1A) . The data showed that the expected high level of N1 IC transgene expression in regressing and nonregressing tumors resulted in upregulation of known Notch1 transcriptional targets, such as Hes1 and Hey1 (18) , and was paralleled by high Myc transcript levels ( Fig.  1 A) . However, the amount of Myc transcripts was not as massive as that observed in the case of MMTV-Myc-induced tumors (Fig. 1B) . The results of Western blot analyses were in agreement with these observations (data not shown). By their third pregnancy, all control mice developed lactationdependent regressing tumors that were readily detectable by visual inspection or palpation. In contrast, palpable masses were absent from the experimental animals, with a single exception (regressing tumor frequency 1͞13 in experimental animals vs. 32͞32 in controls; P Ͻ 10 Ϫ6 ; 2 test). Southern blot analysis of lactating gland DNA indicated that the level of Cre-mediated excision was Ϸ40% (Fig. 1C) , but this is an underestimate, because the tissue includes elements (stromal cells, adipocytes, etc.) in which the Wap promoter is inactive. Moreover, the pattern of Wap expression is normally mosaic (20, 21) . Consistent with these considerations and in agreement with previous reports (22, 23) , Northern blot analysis indicated that, after Cremediated recombination, the level of residual Myc expression in tumor-free lactating glands (''rescued'' by Myc ablation) did not exceed Ϸ20% of the amount detected in regressing neoplasms developed in WT Myc background. (Fig. 1D) .
Conditional Ablation of Myc in Mammary Glands
We conclude that the development of N1 IC -induced palpable regressing tumors depends on unperturbed Myc activity and that residual Myc expression in a small fraction of the epithelial cell population is inadequate for manifestation of a gross phenotype. However, histopathological analysis revealed the presence of microscopic neoplastic lesions that increased in number and size with parity round. Thus, the lactating glands of primiparous experimental females (2 weeks postpartum) contained rare and miniscule solid foci of noninvasive neoplastic lesions, in contrast to WT controls (Fig. 2Aa) . After a second pregnancy, several multifocal noninvasive neoplasms were detected both in alveoli and ducts (Fig.  2 Ab). However, these neoplastic foci were fewer and, on average, 3.7 times smaller than those seen in regressing neoplasms developing in MMTV-N1 IC animals possessing WT Myc (Fig. 2 Ac) . Apparently, the detected microlesions originate from a small minority of cells that escape the Wap-cre action and retain unrecombined, expressible Myc. This conclusion is supported by the following three immunostaining patterns of Notch1 and Myc. In control lactating glands, there is a positive Notch1 signal (Fig. 2Ba ) but no immunodetectable Myc (Fig. 2Bd) . In contrast, in regressing tumors induced by N1 IC in a WT Myc background, the neoplastic areas and the adjacent normal alveoli are positive for both Notch1 and Myc (data not shown). After widespread Myc deletion, however, only the noninvasive microlesions in second-lactation mammary specimens from experimental mice exhibit nuclear staining for Myc, whereas no signal is detectable in adjacent nonneoplastic alveoli (Fig. 2Be ). As expected, the Notch1-positive pattern remains unchanged (Fig. 2Bb) . The presence of microlesions correlated with a high level of proliferation, as assessed by proliferating cell nuclear antigen immunostaining, (50% positivity vs. 10% in adjacent nonneoplastic tissue; data not shown). We note that Myc heterozygosity in the mammary epithelium did not affect the development of palpable regressing neoplasms (n ϭ 13).
Reduced Incidence and Increased Latency in the Development of N1 IC -Induced Nonregressing Mammary Tumors upon Conditional Ablation of Myc.
To examine the impact of Myc absence on the development of nonregressing tumors, we monitored, over a period of 15 months, the described three cohorts of N1 IC transgenic animals that differed in Myc genotype. Control mice (n ϭ 27) possessed functional Myc alleles, whereas, in experimental animals, the Myc alleles were either conditionally ablated (n ϭ 12) or present in the heterozygous state (n ϭ 13) in mammary glands. The results of this genetic analysis are summarized in Fig. 3 .
Nonregressing tumors appeared in controls with a half-time for tumor-free survival (T 50 ) of 7 months (Fig. 3) , and Myc heterozygosity did not change this latency (data not shown). In contrast, only half (6͞12) of the animals with conditionally ablated Myc developed nonregressing carcinomas after a much longer latency period ( Fig.  3 ; T 50 ϭ 12.5 months; P Ͻ 0.0001, log-rank test). Moreover, these tumors were focal and rarely involved more than one breast, whereas the invasive carcinomas in control animals were multifocal and involved several mammary glands, as reported in ref. 12 .
Histopathological analysis and immunostaining showed that the invasive nonregressing tumors had apparently emerged from precancerous lesions originating from Myc-retaining cells. Thus, although all cancer cell nuclei were strongly positive for N1 IC as expected (Fig. 2Bc) , a significant fraction of them also exhibited positive Myc immunostaining (Fig. 2Bf ) . In fact, we were unable to detect histologically identifiable invasive lesions totally lacking immunodetectable Myc. Moreover, a Myc ⌬flox allele was undetectable by Southern blot analysis of DNA extracted from nonregressing tumors of animals possessing an MMTV-N1 IC ͞Myc fl/fl ͞Wap cre genotype (Fig. 1C) . As expected, the cells of the nonregressing tumors were highly proliferative (Ϸ50% of the cells were positive for proliferating cell nuclear antigen immunostaining; data not shown). We also used immunophenotyping to examine whether deregulation of proliferation and inhibition of apoptosis could be correlated with differences between N1 IC -induced tumors and controls in the status of important markers for these processes (see Fig. 7 , which is published as supporting information on the PNAS web site).
Our genetic results clearly demonstrate that Myc is indispensable for the development of N1 IC nonregressing mammary carcinomas appearing with a latency (T 50 ϭ 7 months) significantly shorter than that of tumors developing in MMTV-Myc transgenic mice (T 50 ϭ 8 months; P ϭ 0.008; n ϭ 26; Fig. 3) . Thus, the N1 IC oncogenic process is faster, despite a level of up-regulated Myc that is six times less than that observed in MMTV-Myc animals (Fig. 1B) .
To examine the consequences of very high Myc expression in the context of nonregressing tumor development induced by N1 IC , we also monitored MMTV-N1
IC ͞MMTV-Myc bitransgenic females (n ϭ 12) for the development of carcinomas and observed that they appeared with a T 50 of 5 months (Fig. 3) . This acceleration in tumor progression, which can be attributed to unusually high Myc levels, apparently intensifying the actions of N1 IC , revealed that the two oncogenic transgenes, in addition to their functional relationship, possess other collaborating but nonoverlapping activities. Interestingly, histopathological analysis showed that the tumors of the bitransgenic mice had a ''hybrid'' morphological pattern, exhibiting features characteristic of both N1
IC -and Myc-induced carcinomas (Fig. 2C) .
The Myc Gene Is a Direct Notch1 Transcriptional Target. Considering the causal involvement of Myc overexpression in N1
IC -induced oncogenesis revealed by our genetic analysis, we thought that Myc might be a direct transcriptional target of Notch1. To test this hypothesis, we searched Ϸ1.7 kb of mouse Myc 5Ј flanking sequence upstream from the start site of the most frequently used promoter, P2, (24) and identified three putative Cbf1 binding sites (A-C) with a YTGGGAA motif (Fig. 4A) , which only slightly deviates from the canonical RTGGGAA consensus (3). To examine whether Cbf1 interacts with the Myc promoter region, we performed chromatin immunoprecipitation (ChIP) assays using anti-Notch1 and -Cbf1 antibodies. As Fig. 4B illustrates, these specific antibodies, but not a negative control IgG, were able to immunoprecipitate chromatin, which was enriched in promoter sequences of Myc and of the known Notch1 target genes Hes1 and Hey1 (positive controls), from N1 IC neoplasms. In contrast, the Cdc2a promoter (negative control) was not recognized, although this gene is also overexpressed in N1
IC -induced tumors (data not shown). We note that, in addition to the promoter region, there is a putative Cbf1-binding site in the middle of Myc exon 1, and two other such sites are present in intron 2 (Ϸ200 and 300 bp from the beginning of the intron). None of these sites is conserved in the human Myc locus, and our ChIP assays did not detect enrichment for the sequences that contain them (data not shown), further emphasizing the specificity of binding of a N1
IC -Cbf1 complex in the promoter region.
To establish formally the identity of the candidate Cbf1-binding sites in the Myc promoter, we performed EMSAs using, as probes or competitors, double-stranded oligonucleotides representing intact or mutated versions (3-bp substitutions) of the putative Cbf1 sites B and C (Fig. 4A) and a purified fragment of recombinant mouse Cbf1 (amino acids 203-393) that includes the DNA-binding domain (25) . Fig. 4C shows that the Cbf1 protein fragment was successfully bound to WT duplexes of sites C and B (Myc oligoC and oligoB, respectively) and also to a duplex oligonucleotide containing two adjacent, experimentally verified Cbf1-binding sites of the Hes1 promoter region (positive control). In contrast, mutated versions of the C and B duplexes (Cmut and Bmut) and an unrelated double-stranded DNA fragment corresponding to a loxP site (negative control), failed to form complexes with the Cbf1 fragment. Moreover, an excess of unlabeled Hes1 oligonucleotide, which, as expected, competed successfully with the cognate Hes1-labeled probe for binding to Cbf1, was also able to out-compete the labeled C and B oligonucleotide probes, whereas the unlabeled mutated versions Cmut and Bmut used in excess were ineffective as competitors.
To confirm that the Cbf1 binding sites of the Myc promoter are functional, we performed luciferase reporter assays using 293T cells. In our reporter (mMyc-Luc͞WT; Fig. 5A ), a fragment of the mouse Myc promoter (Ϫ1,662͞ϩ181 in regard to the P2 promoter start site) was connected to the firefly luciferase gene. Reporter DNA was cotransfected with an effector gene plasmid expressing either N1 IC or a chimeric Cbf1-VP16 protein (26) functioning as a transcriptional activator independently of Notch signaling. Although the reporter responded to both N1 IC and Cbf-VP16, the latter effector proved to be a more potent activator. As shown in Fig. 5B , cotransfection of Cbf-VP16 with the mMyc-Luc͞WT reporter resulted reproducibly to an average increase of 2.8-fold in luciferase activity compared with that attained in the absence of an effector (empty pcDNA3 vector control). The corresponding normalized activities of reporter constructs in which one, two, or three of the Cbf1-binding sites were mutated (MutA, MutAB, and MutABC; Fig. 5A ) were consistently Ϸ40% lower (P ϭ 0.003, Student's t test; Fig. 5B) .
By using the same functional assay, we examined whether the human Myc is also a Notch1 target. Alignment of the mouse and human Myc promoter sequences indicated that the Cbf1-binding site A (TTCCCAA) was located in the middle of a highly conserved nucleotide stretch (33͞36 base identities; Fig. 5A ), whereas strong conservation in the regions of sites B and C was not evident (alignment not shown). In the reporters, the luciferase gene was driven by human Myc regulatory sequences (Ϫ389͞ϩ352) that included an intact or a mutated version of site A (hMyc-Luc͞WT and hMyc-Luc͞MutA, respectively). Each of these reporters was cotransfected either with the N1 IC or the Cbf1-VP16 effector plasmid into 293T cells (Cbf1-VP16 again achieved higher stimulation levels). Cotransfection of hMyc-Luc͞WT and Cbf-VP16 resulted in a 3.2-fold increase, on average, in luciferase activity over the level attained with the empty vector. When site A was mutagenized and the hMyc-Luc͞MutA reporter was used in the assay, only a negligible response (1.2-fold relative stimulation) was observed (P ϭ 0.001; Student's t test; Fig. 5B ). To investigate further the functional significance of binding site A while attempting to minimize the dependence of promoter activity on transcription factors other than the N1 IC ͞Cbf1 complex, we generated additional reporters. This time, to drive luciferase gene expression, we linked to a minimal promoter of the Junb gene (Ϫ42͞ϩ136; see ref. 27 ) only short segments of the mouse (Ϫ366͞Ϫ138) and human (Ϫ390͞Ϫ133) Myc sequences containing site A (constructs mMycJunb-Luc͞WT and hMyc-Junb-Luc͞WT, respectively; Fig. 5A ). In the examples shown, chromatin from a nonregressing N1 IC -induced tumor was immunoprecipitated with antibodies against Notch1 (aN1) or Cbf1 (aCbf1) or with control rabbit IgG and analyzed by PCR using primers specific for the indicated promoters. The Myc promoter was analyzed for sites A and B. Hes1 and Hey1 were examined as positive controls; Cdc2a served as a negative control. ''Input'' corresponds to products generated by PCR (still in exponential phase; 25 cycles) by using DNA extracted from nonimmunoprecipitated chromatin (10% of the amount used in experimental samples) as a template. Ϫ, no antibody was added to the reaction mixture. (C) EMSA was performed by using a recombinant Cbf1 protein fragment and the indicated labeled oligonucleotide probes. Myc oligoB and oligoC span, respectively, the corresponding Cbf1 sites shown in A. An oligonucleotide representing two known Cbf1-binding sites of the Hes1 promoter was used as a positive control. (We attribute the shift of two bands to the presence of these two sites.) Mutated versions of Myc oligonucleotides B (Bmut) and C (Cmut) and an unrelated loxP oligonucleotide served as negative controls. In the competition assays, unlabeled Hes1, Bmut, and Cmut oligonucleotides were added to the binding mixture at a 50-fold molar excess.
Robust responses to Cbf1-VP16 were observed with both reporters (Ϸ7-fold and Ϸ9-fold increase in luciferase activity for the mouse and human constructs, respectively), which were diminished upon mutation of site A (see Fig. 5B ).
In summary, when considered together, our three types of molecular analysis provide unequivocal evidence that, at least in mammals, Myc is a direct Notch1 transcriptional target. Whether N1 IC also exerts indirect effects contributing to Myc overexpression during tumor progression cannot be ruled out, but there is no straightforward experiment to test this possibility.
Correlation of Notch1 and Myc Expression in Human Breast Cancer.
Clearly, the potential involvement of deregulated Notch1 expression in the development of human breast cancer merits exploration. Thus, we attempted a preliminary examination of potential Notch1 and Myc coexpression in human breast carcinomas and analyzed immunohistochemically a human breast cancer tissue array by using antibodies that specifically recognize the nuclear form of either Notch1 (N1 IC ) or Myc. In both cases, only readily detectable nuclear staining was considered as relevant for scoring (intensity levels are defined in Methods). First, we evaluated the presence vs. the absence of immunostaining in the carcinomas (n ϭ 128), regardless of signal intensity (Table  1 ). Statistical analysis (Fisher's exact test) indicated that the null hypothesis that the two genes are expressed independently can be overwhelmingly rejected (P Ͻ 10 Ϫ6 ). The same conclusion can be reached by an independent test focusing only on the commonly positive cases (n ϭ 49; Table 2 ) and by evaluating the frequencies of occurrence of the four possible combinations for high and low expression levels of Notch1 and Myc in the examined carcinomas. Again, the statistical analysis indicated that the observed expression levels were not independent but exhibited a high degree of correlation (P ϭ 0.01). Overall, in Ͼ90% of the cases (20͞22) exhibiting high Myc expression, Notch1 was also highly expressed (for an example, see Fig. 2D ).
Discussion
We have shown conclusively that Myc is a direct transcriptional target of aberrant Notch1 signaling, playing an indispensable role in Notch1 IC -induced murine mammary tumorigenesis. It is likely that this relationship is special, because Myc ablation in mammary glands cannot rescue the development of tumors induced by the polyomavirus middle T antigen (S. Koul, K.P., and A.E., unpublished data). Previous in vitro experiments indicated that retroviral transduction of N1 IC into mammalian cells (28, 29) results in up-regulation of Myc expression, but a direct Notch1͞Cbf1 effect on Myc promoter activity was not demonstrated.
In our genetic experiments, N1 IC was unable to cause significant hyperproliferation of the majority of mammary epithelial cells deprived of Myc action, and development of palpable regressing tumors failed during the first pregnancy͞lactation, although a minor fraction of cells had escaped Cre-mediated DNA excision. Even after a second pregnancy, only a few islands of noninvasive neoplastic structures composed of residual Myc-positive cells were encountered. Presumably, such precancerous lesions give rise to nonregressing tumors appearing with reduced incidence and increased latency, perhaps because of a diminished ''target size'' for the occurrence of fruitful secondary carcinogenic events. Our initial Results of reporter assays. 293T cells were cotransfected with Renilla luciferase plasmid and an effector plasmid expressing Cbf1-VP16 or a control plasmid (empty pcDNA3 vector; mock) in combination with one of the indicated reporter plasmids shown in A containing either intact or mutated Cbf1-binding sites. After normalization to Renilla luciferase activity, firefly luciferase activity relative to that of the control plasmid was calculated for each of the reporters. These relative values (mean Ϯ SEM), measured in at least three independent experiments, are represented by the bars in the bar chart. The numbers of cancer specimens in a tissue array that exhibit the indicated immunostaining intensities (defined in Materials and Methods) for Notch1 IC and Myc are listed. For a statistical analysis of the Notch1͞Myc immunostaining combinations, see Results. All specimens, n ϭ 128. Double-positive specimens, n ϭ 49.
attempts to identify such events were unsuccessful. Thus, when we examined N1 IC nonregressing tumors for either Kras (n ϭ 8) or Hras1 (n ϭ 10) potential mutations in codons 12, 13, and 61, differences from WT were not detected.
However, although necessary, Myc is not the sole downstream effector of N1 IC oncogenic action, considering that lactationdependent regressing neoplasms do not appear in MMTV-Myc transgenic mice, whereas their carcinomas develop with a latency longer than that of N1 IC -induced nonregressing tumors, despite a 6-fold higher level of Myc expression. Thus, in addition to Myc, N1 IC also engages other effector(s) toward attainment of a preinvasive and, eventually, a malignant state. Nevertheless, highly expressed MMTV LTR-driven Myc appears to exert more pleiotropic effects than Myc up-regulation by way of Notch1͞Cbf1 action, as can be surmised from the significant reduction in latency of nonregressing tumors caused by the combined actions of MMTV-N1 IC and MMTV-Myc transgenes.
It is thought that, because Notch signaling controls cell fate decisions and blocks differentiation depending on cellular context, it could promote tumorigenesis by analogous action when deregulated (4). Such a model of arrested differentiation appears consistent with the mammary oncogenic activity of constitutively expressed Notch4 IC that leads to dysmorphogenesis, preventing the appearance of milk-producing lobules (30) . Clearly, however, the model is not tenable for Notch1 IC , because the process of mammary differentiation remains unperturbed, and the lactating females are capable of nursing their pups despite the appearance of regressing tumors. A proliferative rather than a differentiation defect is therefore a more likely working model for the development of N1 IC tumors, especially in view of the crucial participation of Myc. In fact, based on the key observation that morphologically identifiable Myc-negative invasive lesions were not detected, we propose that at least the proliferative function of Myc (directly demonstrated by positive proliferating cell nuclear antigen staining) is an obligatory component of the circuitry that, in the context of N1 IC -mediated events, must remain intact as a favorable precondition for the eventual manifestation of full-fledged malignancy.
Our results provide still another example of the importance of modeling cancer in mice and of the powerful combination of genetic and molecular analyses to establish causal and mechanistic relationships between concerted tumorigenic activities in aberrant signaling networks, such as those involving Notch1 and Myc. Moreover, the unraveling of a Notch1͞Myc relationship by using our mouse model prompted an investigation that documented a strong association between high levels of Notch1 and Myc expression in human breast cancers. (31) and Wap-cre (17) strains of mice have been described previously. Our breeding program is described in Supporting Materials and Methods, which is published as supporting information on the PNAS web site.
Materials and Methods
Molecular Analyses. ChIP experiments were performed as described in ref. 32 . For luciferase assays, we used pGL3 and the Dual Luciferase Assay kit (Promega). The point of reference for all mouse and human Myc sequence coordinates is the promoter P2 start site. Microarray analyses with Affymetrix (Santa Clara, CA) MGU74Av2 DNA chips were performed as described in ref. 33 . Southern and Northern blot analyses and descriptions of probes, ChIP assays, EMSA, and the plasmids used for luciferase assays can be found in Supporting Materials and Methods.
Histological Analyses. The antibodies used for immunophenotyping are listed in Supporting Materials and Methods. The results of tissue array immunostaining were scored as ''negative'' (absence of nuclear staining), ''weakly positive'' (low, Ͻ15% of the nuclei exhibiting strong immunoreactivity), and ''strongly positive'' (high, Ն15% of the nuclei exhibiting intense immunoreactivity).
